Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.

[1]  M. Hadamitzky,et al.  Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial. , 2019, European heart journal.

[2]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[3]  P. Groeneveld,et al.  Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016 , 2018, JAMA internal medicine.

[4]  M. Hadamitzky,et al.  Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial , 2018, European heart journal.

[5]  J. Chen,et al.  Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial , 2018, Circulation.

[6]  D. Capodanno,et al.  Trials of antithrombotic therapy in percutaneous coronary intervention: what evidence do we need to optimise our practice? , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[7]  M. Price,et al.  Pharmacogenomic Testing to Select Antiplatelet Therapy. , 2018, Journal of the American College of Cardiology.

[8]  Julie A. Johnson,et al.  Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention , 2018, Journal of Translational Medicine.

[9]  G. Stouffer,et al.  Clinical Outcomes and Sustainability of Using CYP2C19 Genotype–Guided Antiplatelet Therapy After Percutaneous Coronary Intervention , 2018, Circulation. Genomic and precision medicine.

[10]  W. Ageno,et al.  A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2. , 2018, JACC. Cardiovascular interventions.

[11]  Diego Ardissino,et al.  Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial. , 2018, Journal of the American College of Cardiology.

[12]  J. Moon,et al.  Role of genetic testing in patients undergoing percutaneous coronary intervention , 2018, Expert review of clinical pharmacology.

[13]  Joshua C Denny,et al.  Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. , 2018, JACC. Cardiovascular interventions.

[14]  J. Moon,et al.  Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. , 2017, Progress in cardiovascular diseases.

[15]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[16]  P. Kolh,et al.  [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.

[17]  Deepak L. Bhatt,et al.  International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies , 2017, Circulation.

[18]  P. Morange,et al.  Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study , 2017, European heart journal.

[19]  D. Angiolillo.  Dual antiplatelet therapy guided by platelet function testing , 2017, The Lancet.

[20]  M. Hadamitzky,et al.  Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial , 2017, The Lancet.

[21]  S. de Servi,et al.  Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[22]  K. Anstrom,et al.  Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE‐ACS) obse , 2017, American heart journal.

[23]  C. Dávila-Fajardo,et al.  Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent. , 2016, International journal of cardiology.

[24]  E. Vicaut,et al.  Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial , 2016, The Lancet.

[25]  D. Sibbing,et al.  Antiplatelet strategies in elderly people: still a long way to go , 2016, The Lancet.

[26]  B. Deiman,et al.  Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands , 2016, Netherlands Heart Journal.

[27]  Deepak L. Bhatt,et al.  Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. , 2016, Journal of the American College of Cardiology.

[28]  Bo Wang,et al.  Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population , 2016, Journal of cardiovascular pharmacology.

[29]  R. McPherson,et al.  A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study , 2015, The Pharmacogenomics Journal.

[30]  E. Vicaut,et al.  Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome , 2015, Thrombosis and Haemostasis.

[31]  Peter L Duffy,et al.  Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). , 2015, JACC. Cardiovascular interventions.

[32]  Peter L Duffy,et al.  Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. , 2015, Journal of the American College of Cardiology.

[33]  D. Sargent,et al.  Genotype-based clinical trials in cardiovascular disease , 2015, Nature Reviews Cardiology.

[34]  M. Price,et al.  Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. , 2015, European heart journal.

[35]  J. Mega,et al.  Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI , 2014, Nature Reviews Cardiology.

[36]  M. Postma,et al.  CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. , 2014, American heart journal.

[37]  C. Cannon,et al.  Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial , 2014, European heart journal.

[38]  H. Schunkert,et al.  A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity , 2014, Thrombosis and Haemostasis.

[39]  B. Baker,et al.  Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification , 2014, Journal of thrombosis and haemostasis : JTH.

[40]  Eric D. Peterson,et al.  Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry , 2014, Journal of the American Heart Association.

[41]  G. Veress,et al.  Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. , 2014, Journal of the American College of Cardiology.

[42]  K. Huber,et al.  Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention , 2013, European heart journal.

[43]  Deepak L. Bhatt,et al.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.

[44]  Xiang Ma,et al.  Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. , 2013, International journal of cardiology.

[45]  M. Price,et al.  Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. , 2013, International journal of cardiology.

[46]  J. O’Connell,et al.  The CYP2C19*17 variant is not independently associated with clopidogrel response , 2013, Journal of thrombosis and haemostasis : JTH.

[47]  G. Maurer,et al.  Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. , 2013, International journal of cardiology.

[48]  J. Mega,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[49]  Peter L Duffy,et al.  Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.

[50]  E. Vicaut,et al.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting. , 2012, The New England journal of medicine.

[51]  Deepak L. Bhatt,et al.  The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. , 2012, European heart journal.

[52]  Selma Ari,et al.  The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial). , 2012, International journal of cardiology.

[53]  G. Stone,et al.  A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem , 2012, Journal of the American College of Cardiology.

[54]  N. Schork,et al.  Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. , 2012, Journal of the American College of Cardiology.

[55]  Edward O'Brien,et al.  Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial , 2012, The Lancet.

[56]  D. Aradi,et al.  Justification of 150 mg clopidogrel in patients with high on‐clopidogrel platelet reactivity , 2012, European journal of clinical investigation.

[57]  P. Rehak,et al.  Platelet Function Measurement–Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery: The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study , 2012, Circulation. Cardiovascular interventions.

[58]  D. Aradi,et al.  Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention , 2012, Journal of Thrombosis and Thrombolysis.

[59]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[60]  M. Pencina,et al.  Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. , 2011, JAMA.

[61]  Yan Lai,et al.  Modifying Clopidogrel Maintenance Doses According to Vasodilator‐Stimulated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance , 2011, Clinical cardiology.

[62]  P. Gurbel,et al.  Peri-operative platelet function testing: The potential for reducing ischaemic and bleeding risks , 2011, Thrombosis and Haemostasis.

[63]  N. Schork,et al.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. , 2011, JAMA.

[64]  E. Antman,et al.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.

[65]  Deepak L. Bhatt,et al.  Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. , 2010, The New England journal of medicine.

[66]  R. Ferrari,et al.  Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. , 2010, Journal of the American College of Cardiology.

[67]  E. Antman,et al.  Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis , 2010, The Lancet.

[68]  B. J. Barratt,et al.  Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial , 2010, The Lancet.

[69]  Deepak L. Bhatt,et al.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.

[70]  S. Steinhubl,et al.  Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. , 2010, Journal of the American College of Cardiology.

[71]  A. Shuldiner,et al.  Genotyping: one piece of the puzzle to personalize antiplatelet therapy. , 2010, Journal of the American College of Cardiology.

[72]  M. Fromm,et al.  Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. , 2010, Journal of the American College of Cardiology.

[73]  A. Kastrati,et al.  Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement , 2010, Circulation.

[74]  S. Werns.  Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes , 2010 .

[75]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[76]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[77]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[78]  R. Ferrari,et al.  Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance , 2009, Circulation.

[79]  Jessica L Mega,et al.  Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes , 2009, Circulation.

[80]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[81]  Adnan Kastrati,et al.  Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. , 2009, Journal of the American College of Cardiology.

[82]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[83]  A. Kastrati,et al.  Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. , 2008, European heart journal.

[84]  Françoise Dignat-George,et al.  Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. , 2009, The American journal of cardiology.

[85]  P. Morange,et al.  Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. , 2008, JACC. Cardiovascular interventions.

[86]  E. Antman,et al.  Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. , 2008, Journal of the American College of Cardiology.

[87]  P. Barragan,et al.  Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. , 2008, Journal of the American College of Cardiology.

[88]  Matthew J Price,et al.  Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. , 2008, European heart journal.

[89]  Deepak L. Bhatt.  Intensifying platelet inhibition--navigating between Scylla and Charybdis. , 2007, The New England journal of medicine.

[90]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[91]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[92]  D. Angiolillo,et al.  Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study , 2007, Circulation.

[93]  A. Bura,et al.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.

[94]  P. Gurbel,et al.  Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. , 2005, Journal of the American College of Cardiology.

[95]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[96]  M. Bertrand,et al.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.

[97]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.